Bispecific T‐cell engagers for treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26628
Abstract: Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs promote T cell activation and lysis of… read more here.
Keywords: cell engagers; cell; multiple myeloma; bispecific cell ... See more keywords
Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.651
Abstract: Bispecific T‐cell Engagers (BiTE®) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab,… read more here.
Keywords: bite antibody; bispecific cell; pharmacology; cell ... See more keywords
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04221-0
Abstract: The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is… read more here.
Keywords: bispecific cell; cell malignancies; immuno oncology; cell engager ... See more keywords
Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats
Sign Up to like & getrecommendations! Published in 2020 at "Current Medical Science"
DOI: 10.1007/s11596-020-2143-y
Abstract: Selecting an ideal molecular format from diverse structures is a major challenge in developing a bispecific antibody (BsAb). To choose an ideal format of anti-CD3 × anti-transferrin receptor (TfR) bispecific antibodies for clinical application, we… read more here.
Keywords: chain; bispecific cell; anti transferrin; cell engager ... See more keywords
Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2017.1396890
Abstract: ABSTRACT Introduction: Immunotherapy is a promising modality of treatment of neoplastic diseases, including acute lymphoblastic leukemia (ALL). The CD19/CD3-bispecific T cell–engaging (BiTE®) monoclonal antibody blinatumomab can transiently bind cytotoxic T cells to CD19+ target B… read more here.
Keywords: bispecific cell; cell; safety; lymphoblastic leukemia ... See more keywords
Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2018.1540928
Abstract: ABSTRACT Introduction: The clinical application of immunotherapy has resulted into a significant improvement in the outcome of children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL). In this setting, the use of bispecific T-cell-engager… read more here.
Keywords: bispecific cell; cell; acute lymphoblastic; lymphoblastic leukemia ... See more keywords
ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz219.1195
Abstract: The class III variant of the epidermal growth factor receptor (EGFRvIII) represents the most common EGFR mutation in GBM. AMG 596 is a bispecific T cell engager (BiTE®) molecule designed to engage a patient’s own… read more here.
Keywords: bispecific cell; gbm; analysis; treatment ... See more keywords
Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abn0402
Abstract: Cystine-dense peptides (CDPs) are a miniprotein class that can drug difficult targets with high affinity and low immunogenicity. Tools for their design, however, are not as developed as those for small-molecule and antibody drugs. CDPs… read more here.
Keywords: cell engager; cdp; dense; cystine dense ... See more keywords
NKG2D Ligand–Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-16-0846
Abstract: Two new bispecific T-cell engaging (BiTE) molecules with specificity for NKG2D ligands were developed and functionally characterized. One, huNKG2D-OKT3, was derived from the extracellular portion of the human NKG2D receptor fused to a CD3ϵ binding… read more here.
Keywords: bispecific cell; hunkg2d okt3; robust antitumor; okt3 ... See more keywords
Abstract 1542: Bispecific T cell engager-induced toxicity in an immunocompetent solid tumor model
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-1542
Abstract: Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers have demonstrated clinical efficacy, however are often accompanied by severe toxicity including cytokine release syndrome (CRS), neurotoxicity or macrophage activation syndrome (MAS). Mechanistic understanding… read more here.
Keywords: toxicity; induced toxicity; bispecific; tumor ... See more keywords
Visualizing Spatial and Stoichiometric Barriers to Bispecific T-cell Engager Efficacy.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-21-0594
Abstract: Bispecific T-cell engager (BiTE) molecules are biologic T cell-directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here, we employed intravital imaging to… read more here.
Keywords: cell engager; cell; bite molecule; efficacy ... See more keywords